Precision generalized phase I--II designs

DOI10.1093/BIOMTC/UJAF043MaRDI QIDQ6905161zbMATH OpenFDO

Authors Saijun Zhao, Peter F. Thall, Ying Yuan, Juhee Lee, Pavlos Msaouel, Y. Zang

Publication date 6 November 2025

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://hdl.handle.net/1805/50215

zbMATH Keywords

Bayesian adaptive designcell therapydose optimizationphase I--II clinical trialsprecision medicine

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• Analysis of multivariate probit models
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Phase I/II design for selecting subgroup-specific optimal biological doses for prespecified subgroups
• Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups
• Reversible jump Markov chain Monte Carlo computation and Bayesian model determination

This page was built for publication: Precision generalized phase I--II designs

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6905161)